Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 140Head and Neck Neoplasms 114Carcinoma, Non-Small-Cell Lung 49Thyroid Neoplasms 42Melanoma 36Nasopharyngeal Carcinoma 35Mouth Neoplasms 35Ovarian Neoplasms 30Breast Neoplasms 30Oropharyngeal Neoplasms 29Colorectal Neoplasms 29Neoplasm Metastasis 26Uterine Cervical Neoplasms 24Lung Neoplasms 22Neoplasms 20Carcinoma, Squamous Cell 20Carcinoma, Renal Cell 20Carcinoma 19Stomach Neoplasms 18Pancreatic Neoplasms 17Prostatic Neoplasms 16Esophageal Neoplasms 16Endometrial Neoplasms 16Triple Negative Breast Neoplasms 15Laryngeal Neoplasms 15Sarcoma 14Urinary Bladder Neoplasms 13Hypopharyngeal Neoplasms 12Carcinoma, Transitional Cell 12Salivary Gland Neoplasms 11

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lip Neoplasms × Head & Neck × 30 days × Clear all
NCT07552558 2026-06-03

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Washington University School of Medicine

Phase 1/2 Not yet recruiting
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡